

NOVAVAX INC  
Form 8-K  
November 04, 2004

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT PURSUANT TO 13 or 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported): November 3, 2004

**NOVAVAX, INC.**

(Exact name of registrant as specified in its charter)

<b><u>Delaware</u></b> (State or other jurisdiction of incorporation or organization)	<b><u>0-26770</u></b> (Commission File No.)	<b><u>22-2816046</u></b> (I.R.S. Employer Identification No.)
---	---	---

<b><u>508 Lapp Road, Malvern,</u></b> <b><u>Pennsylvania</u></b> (Address of principal executive offices)	<b><u>19355</u></b> (Zip code)
--	-----------------------------------

**(484) 913-1200**  
Registrant's telephone number, including area code

**Not applicable**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**NOVAVAX, INC.  
ITEMS TO BE INCLUDED IN THIS REPORT**

**ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION.**

On November 3, 2004, Novavax, Inc. reported its third quarter earnings for 2004.

A copy of the Press Release is attached hereto as Exhibit 99.1 and incorporated herein by reference.

**ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.**

(c) Exhibits.

99.1 Press Release dated November 3, 2004.

---

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: November 4, 2004

NOVAVAX, INC.  
By: /s/ Dennis W. Genge

---

Dennis W. Genge  
Vice President and Chief  
Financial Officer